Top

BMC Public Health

Published in:

Open Access 01-12-2021 | Lymphoma | Research article

Non Hodgkin lymphoma in Lebanon: a retrospective epidemiological study between 1984 and 2019

Authors: Elsie Touma, Leony Antoun, Souheil Hallit, Fadi Nasr, Marcel Massoud, Radwan El Othman, Georges Chahine

Published in: BMC Public Health | Issue 1/2021

Abstract

Background

Lymphomas are ranked as the fifth most common cancer in Lebanon. There is concern about the need of information regarding the prevalence of lymphoid neoplasm particularly Non-Hodgkin lymphoma (NHL) subtypes in the Lebanese population. This study intended to establish a descriptive status of NHL histological subtypes distribution in Lebanon thus identifying the most common types, knowing that the literature is poor regarding the distribution of lymphoid malignancies particularly NHLs in Lebanon.

Methods

A bicenter retrospective descriptive study was performed. Patients aged above 18, diagnosed with NHL between January 1984 and March 2019 and registered in two Lebanese Medical centers were included in this study; 699 medical files were reviewed and the baseline characteristics of the disease were collected. Histological classification was based on the Working Formulation (WF) and World Health Organization (WHO) classification systems, whereas staging was based on the Ann Arbor system. Disease status was monitored with imaging studies.

Results

The mean age at diagnosis was 53.52 ± 17.46 years in the studied population, with 380 (54.4%) males and 319 (45.6%) females. B-cell lymphoma (BCL) accounted for 86.3% while T-cell neoplasms accounted for 13.7%. The most common subtype was diffuse large B-cell lymphoma (DLBCL) (54%) followed by follicular lymphoma (FL) (17.2%). Mantle cell lymphoma (MCL) represented 3% of all BCL and small lymphocytic lymphoma (SLL) comprised less than 2%. Mucosa-associated lymphoid tissue (MALT) and Burkitt’s lymphomas represented 3 and 1.7% respectively. 36.5% of the patients had extranodal disease at diagnosis. High-grade tumor represented 80.1% with 33.1% stage IV disease.

Conclusion

These observations indicate that the epidemiological patterns of NHLs in Lebanon were comparable to Western countries. Aggressive lymphomas account for the majority of NHLs in Lebanon.

Sader-Ghorra C, Rassy M, Naderi S, Kourie HR, Kattan J. Type distribution of lymphomas in Lebanon: five-year single institution experience. Asian Pac J Cancer Prev. 2014;15(14):5825–8. https://doi.org/10.7314/APJCP.2014.15.14.5825.CrossRefPubMed

Shamseddine A, Saleh A, Charafeddine M, Seoud M, Mukherji D, Temraz S, et al. Cancer trends in Lebanon: a review of incidence rates for the period of 2003–2008 and projections until 2018. Popul Health Metrics. 2014;12(1):4. https://doi.org/10.1186/1478-7954-12-4.CrossRef

Nair R, Arora N, Mallath MK. Epidemiology of non-Hodgkin’s lymphoma in India. Oncology. 2016;91(1):18–25. https://doi.org/10.1159/000447577.CrossRefPubMed

Sandhu DS, Sharma A, Kumar L. Non-Hodgkin’s lymphoma in northern India: an analysis of clinical features of 241 cases. Indian J Med Paediatr Oncol. 2018;39(1):42–5. https://doi.org/10.4103/ijmpo.ijmpo_36_17.CrossRef

Evans LS, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2003;362(9378):139–46. https://doi.org/10.1016/S0140-6736(03)13868-8.CrossRefPubMed

Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012;380(9844):848–57. https://doi.org/10.1016/S0140-6736(12)60605-9.CrossRefPubMed

Casan JML, Wong J, Northcott MJ, Opat S. Anti-CD20 monoclonal antibodies: reviewing a revolution. Hum Vaccin Immunother. 2018;14(12):2820–41. https://doi.org/10.1080/21645515.2018.1508624.CrossRefPubMedPubMedCentral

Müller AMS, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol. 2005;84(1):1–12. https://doi.org/10.1007/s00277-004-0939-7.CrossRefPubMed

Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. SEER Cancer Statistics Review, 1975–2002. ed. Bethesda: National Cancer Institute; 2005.

10.

El-Attar IA. Cancer databases in the Arab world. Ethn Dis. 2005;15(1 Suppl 1):S1-3-4.

11.

Miranda-Filho A, Piñeros M, Znaor A, Marcos-Gragera R, Steliarova-Foucher E, Bray F. Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer Causes Control. 2019;30(5):489–99. https://doi.org/10.1007/s10552-019-01155-5.CrossRefPubMed

12.

National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. The non-Hodgkin’s lymphoma pathologic classification project. Cancer. 1982;49(10):2112–35. https://doi.org/10.1002/1097-0142(19820515)49:10<2112::aid-cncr2820491024>3.0.co;2-2.

13.

Zerbini MCN, Soares FA, Paes RP. World Health Organization classification of tumors of hematopoietic and lymphoid tissues, 4th edition, 2008 – major changes from the 3rd edition, 200. Rev Assoc Med Bras. 2008;8:7.

14.

Armitage JO. Staging Non-Hodgkin Lymphoma. CA Cancer J Clin. 2005;55(6):368–76. https://doi.org/10.3322/canjclin.55.6.368.CrossRefPubMed

15.

Lee JS, Bracci PM, Holly EA. Non-Hodgkin lymphoma in women: reproductive factors and exogenous hormone use. Am J Epidemiol. 2008;168(3):278–88. https://doi.org/10.1093/aje/kwn119.CrossRefPubMedPubMedCentral

16.

Horesh N, Horowitz NA. Does gender matter in non-Hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy. Rambam Maimonides Med J. 2014;5(4):e0038. https://doi.org/10.5041/RMMJ.10172.CrossRefPubMedPubMedCentral

17.

Yakimchuk K, Iravani M, Hasni MS, Rhönnstad P, Nilsson S, Jondal M, et al. Effect of ligand-activated estrogen receptor beta on lymphoma growth in vitro and in vivo. Leukemia. 2011;25(7):1103–10. https://doi.org/10.1038/leu.2011.68.CrossRefPubMed

18.

Perry AM, Diebold J, Nathwani BN, MacLennan KA, Muller-Hermelink HK, Bast M, et al. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the international non-Hodgkin lymphoma classification project. Haematologica. 2016;101(10):1244–50. https://doi.org/10.3324/haematol.2016.148809.CrossRefPubMedPubMedCentral

19.

Gijsbers van Wijk CM, van Vliet KP, Kolk AM. Gender perspectives and quality of care: towards appropriate and adequate health care for women. Soc Sci Med. 1996;43(5):707–20. https://doi.org/10.1016/0277-9536(96)00115-3.CrossRefPubMed

20.

Koriech OM. Al-Kuhaymi Rashid. Profile of Cancer in Riyadh armed forces hospital. Annals of Saudi Medicine. 1994;14(3):187–94. https://doi.org/10.5144/0256-4947.1994.187.CrossRefPubMed

21.

Almasri NM, Habashneh MA, Khalidi HS. Western Asia to the Middle East to Northern Africa; 2003.

22.

Abdel-Fattah MM, Yassine OG. Non-Hodgkin’s lymphomas in Alexandria, Egypt; incidence rates and trend study (1995–2004). Eur J Cancer Prev. 2007;16(5):479–85. https://doi.org/10.1097/01.cej.0000243858.91642.c9.CrossRefPubMed

23.

Intragumtornchai T, Bunworasate U, Wudhikarn K, Lekhakula A, Julamanee J, Chansung K, et al. Non-Hodgkin lymphoma in South East Asia: an analysis of the histopathology, clinical features, and survival from Thailand. Hematol Oncol. 2018;36(1):28–36. https://doi.org/10.1002/hon.2392.CrossRefPubMed

24.

Lymphoma Action | T-cell lymphomas. Lymphoma Action. https://lymphoma-action.org.uk/types-lymphoma-non-hodgkin-lymphoma/t-cell-lymphomas

25.

Troussard X, Duchenet V, Cornet E, Mouchel D, Malet M, Collignon A. Épidémiologie des hémopathies malignes en Basse-Normandie. Rev Epidemiol Sante Publique. 2009;57(3):151–8. https://doi.org/10.1016/j.respe.2009.02.204.CrossRefPubMed

26.

Types of T-cell Lymphoma. https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/t-cell-lymphoma.html

27.

Yang Q-P, Zhang W-Y, Yu J-B, Zhao S, Xu H, Wang WY, et al. Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol. 2011;6(1):77. https://doi.org/10.1186/1746-1596-6-77.CrossRefPubMedPubMedCentral

28.

Aoki R, Karube K, Sugita Y, Nomura Y, Shimizu K, Kimura Y, et al. Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001-2006. Pathol Int. 2008;58(3):174–82. https://doi.org/10.1111/j.1440-1827.2007.02207.x.CrossRefPubMed

29.

Otrock ZK, Saab J, Aftimos G, Nasr F, Farhat FS, Khairallah S, et al. A collaborative Nationwide lymphoma study in Lebanon: incidence of various subtypes and analysis of associations with viruses. Pathol Oncol Res. 2013;19(4):715–22. https://doi.org/10.1007/s12253-013-9634-0.CrossRefPubMed

30.

Boudjerra N, Perry AM, Audouin J, Diebold J, Nathwani BN, MacLennan KA, et al. Classification of non-Hodgkin lymphoma in Algeria according to the World Health Organization classification. Leuk Lymphoma. 2015;56(4):965–70. https://doi.org/10.3109/10428194.2014.939967.CrossRefPubMed

31.

Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, et al. Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK’s Haematological malignancy research network. Br J Cancer. 2015;112(9):1575–84. https://doi.org/10.1038/bjc.2015.94.CrossRefPubMedPubMedCentral

32.

Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164(4):536–45. https://doi.org/10.1111/bjh.12659.CrossRefPubMed

33.

Akhtar SS, Haque I, Wafa SM, El-Saka H, Saroor AM, Nadrah HM. Malignant lymphoma in Al-Qassim, Saudi Arabia, reclassified according to the WHO classification. Saudi Med J. 2009;30(5):677–81.PubMed

34.

Wu X-C, Andrews P, Chen VW, Groves FD. Incidence of extranodal non-Hodgkin lymphomas among whites, blacks, and Asians/Pacific islanders in the United States: anatomic site and histology differences. Cancer Epidemiol. 2009;33(5):337–46. https://doi.org/10.1016/j.canep.2009.09.006.CrossRefPubMed

35.

Quero L, Hennequin C, Brice P. Place de la radiothérapie dans le traitement des lymphomes non hodgkiniens. Cancer/Radiothérapie. 2009;13(6):471–8. https://doi.org/10.1016/j.canrad.2009.07.005.CrossRef

36.

Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100(1):86–92. https://doi.org/10.1016/j.radonc.2011.05.013.

37.

Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339(1):21–6. https://doi.org/10.1056/NEJM199807023390104.CrossRefPubMed

38.

Connors JM, Klimo P, Fairey RN, Voss N. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Intern Med. 1987;107(1):25–30. https://doi.org/10.7326/0003-4819-107-1-25.CrossRefPubMed

39.

Phan J, Mazloom A, Jeffrey Medeiros L, Zreik TG, Wogan C, Shihadeh F, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. JCO. 2010;28(27):4170–6. https://doi.org/10.1200/JCO.2009.27.3441.CrossRef

Title: Non Hodgkin lymphoma in Lebanon: a retrospective epidemiological study between 1984 and 2019
Authors: Elsie Touma
Leony Antoun
Souheil Hallit
Fadi Nasr
Marcel Massoud
Radwan El Othman
Georges Chahine
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Lymphoma
Non-Hodgkin Lymphoma
Mantle Cell Lymphoma
Radiotherapy
Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Published in: BMC Public Health / Issue 1/2021
Electronic ISSN: 1471-2458
DOI: https://doi.org/10.1186/s12889-021-11840-3

At a glance: The STEP trials

Springer Medicine

Non Hodgkin lymphoma in Lebanon: a retrospective epidemiological study between 1984 and 2019

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Neonatal mortality burden and trends in UNHCR refugee camps, 2006–2017: a retrospective analysis

Differential impact of mitigation policies and socioeconomic status on COVID-19 prevalence and social distancing in the United States

Towards a needs-based design of the physical rehabilitation workforce in South Africa: trend analysis [1990–2017] and a 5-year forecasting for the most impactful health conditions based on global burden of disease estimates

Parental support and monitoring as associated with adolescent alcohol and tobacco use by gender and age

Examining the relationship between food insecurity and causes of injury in Canadian adults and adolescents

The “anti-vax” movement: a quantitative report on vaccine beliefs and knowledge across social media